✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Penicillins (amoxicillin, amoxicillin/clavulanate) remain first-line for many common bacterial infections — narrow enough to limit resistance, broad enough to cover the usual suspects.
- Macrolides (azithromycin, erythromycin, clarithromycin) are the go-to for atypical respiratory infections and beta-lactam allergy.
- Tetracyclines (doxycycline) cover atypicals, Lyme, acne, and many travel-medicine indications without needing IV access.
- Fluoroquinolones (levofloxacin, ciprofloxacin) are powerful but reserved — black-box warnings for tendon, neurological, and aortic effects.
- Below: 10 best antibiotic options across the major drug classes — match the molecule to the suspected infection, not the other way around.
Best Antibiotics in 2026: 10 Evidence-Backed Picks for Common Bacterial Infections
Choosing the right antibiotic is class-driven and infection-driven. The 2024 BSAC and 2024 IDSA guidelines emphasise narrow-spectrum first-line options to slow resistance development, with broader-spectrum reserves for confirmed or suspected resistant pathogens. This guide covers the 10 most-used antibiotics across penicillin, cephalosporin, macrolide, tetracycline, fluoroquinolone, and nitroimidazole classes — with mechanism, indication match, and decision shortcuts.
Important: antibiotics are not the right treatment for viral infections (colds, flu, most sore throats and bronchitis). Inappropriate antibiotic use accelerates resistance and exposes you to side effects without benefit. If symptoms suggest a viral cause and you’re otherwise healthy, supportive care is usually the answer. When you’re unsure whether your infection needs antibiotics, a clinician can examine you, order tests if needed, and pick the right narrow-spectrum option.
How antibiotic choice is structured
Modern antibiotic selection considers four axes: spectrum (which bacteria the drug covers), penetration (does the drug reach the infection site — bone, CSF, prostate, lung), resistance pattern (local susceptibility data and patient risk factors for resistant strains), and side-effect profile (kidney function, drug interactions, allergies, age). The ideal antibiotic is the narrowest one that reliably covers the suspected pathogen — broader is not better.
Course length matters too. Many infections previously treated for 7–14 days now have evidence for shorter courses (3–5 days for uncomplicated UTI, 5–7 days for community-acquired pneumonia, 5 days for cellulitis when uncomplicated). The “always finish the course” advice is being reassessed — for many infections, the shortest effective course minimises both resistance pressure and side effects.
1. Mox (Amoxicillin 250/500 mg)
Class: Aminopenicillin · Manufacturer: WHO-GMP certified · View product
Amoxicillin is the workhorse first-line antibiotic for many common community infections — strep throat, otitis media, sinusitis, dental infections, mild community-acquired pneumonia, Lyme disease (children), and Helicobacter pylori eradication regimens. Excellent oral bioavailability, well-tolerated, narrow-enough spectrum to limit downstream resistance pressure. Standard dosing 500 mg three times daily; high-dose pneumococcal coverage can require 1 g three times daily.
Side effects: diarrhoea (~5–10%), rash (especially in undiagnosed mononucleosis — almost universal), nausea. True penicillin allergy is rare (~1%); most reported “penicillin allergies” don’t reproduce on careful re-challenge.
Pick for: uncomplicated otitis media, sinusitis, strep throat, mild community-acquired pneumonia, dental abscess.
2. Augmentin (Amoxicillin 500 mg + Clavulanic Acid 125 mg)
Class: Aminopenicillin + beta-lactamase inhibitor · Manufacturer: GSK · View product
Augmentin (co-amoxiclav) extends amoxicillin’s spectrum by neutralising bacterial beta-lactamase enzymes. Coverage now includes beta-lactamase-producing strains of H. influenzae, Moraxella catarrhalis, S. aureus (methicillin-sensitive), and many anaerobes. Useful when amoxicillin alone is inadequate — recurrent or treatment-failed otitis media, sinusitis with severe symptoms, animal bites, diabetic foot infections, complicated UTIs.
Side effects: diarrhoea (~15–25% — much higher than amoxicillin alone, mostly from clavulanate), cholestatic hepatitis (rare but characteristic), rash. Take with food to minimise GI upset.
Pick for: animal/human bite wounds, recurrent or severe sinusitis/otitis, diabetic foot infections, complicated UTIs.
3. Cephadex (Cephalexin 250/500 mg)
Class: First-generation cephalosporin · Manufacturer: Cipla · View product
Cephalexin is the reference oral first-generation cephalosporin — narrow spectrum focused on gram-positive cocci (S. aureus methicillin-sensitive, streptococci) and select gram-negatives. Workhorse for uncomplicated skin and soft tissue infections (cellulitis, impetigo, post-surgical wound infection), simple UTIs in pregnancy, and Group B streptococcal prophylaxis.
Side effects: diarrhoea, rash, transient transaminitis. Cross-reactivity with penicillin allergy is much lower than older estimates suggested (~1–2% in true IgE-mediated penicillin allergy, near-zero with non-anaphylactic histories).
Pick for: uncomplicated cellulitis, simple UTI in pregnancy, post-surgical prophylaxis, mastitis.
4. Cefix (Cefixime 100/200 mg)
Class: Third-generation cephalosporin (oral) · Manufacturer: WHO-GMP certified · View product
Cefixime is the most-used oral third-generation cephalosporin — broader gram-negative coverage than Cephadex, including most Enterobacterales and N. gonorrhoeae (though IM ceftriaxone is now preferred for gonorrhoea due to resistance trends). Useful for complicated UTIs, typhoid (alternative to fluoroquinolones in resistant areas), and step-down from IV ceftriaxone in respiratory infections.
Pick for: typhoid fever (in fluoroquinolone-resistant areas), complicated UTI, gonorrhoea where IM ceftriaxone is unavailable, step-down from IV cephalosporin.
5. Asitomycin 500 (Azithromycin 500 mg)
Class: Macrolide · Manufacturer: WHO-GMP certified · View product
Azithromycin’s main feature is short courses — 3-day or 5-day regimens with effectiveness equal to longer courses of older antibiotics. Mechanism: 50S ribosomal binding inhibits bacterial protein synthesis. Spectrum: atypical respiratory pathogens (Mycoplasma, Chlamydia, Legionella), respiratory streptococci, Helicobacter pylori, sexually-transmitted infection (single 1 g dose for chlamydia). Long tissue half-life means 5-day course gives ~10 days of antibacterial activity.
Side effects: GI upset (diarrhoea, abdominal pain), QT prolongation (caution with other QT-prolonging drugs), reversible hearing changes at high doses, hepatotoxicity rare but notable.
Pick for: community-acquired pneumonia (especially atypical), chlamydia, traveller’s diarrhoea, COPD exacerbation, beta-lactam-allergic patients.
6. Erythromycin (250 mg)
Class: Macrolide · Manufacturer: WHO-GMP certified · View product
Erythromycin is the original macrolide — older, more-side-effect-laden, but still useful in specific niches. Pertussis prophylaxis and treatment in pregnancy (azithromycin preferred but erythromycin also accepted), gastroparesis (low-dose erythromycin’s prokinetic motilin-receptor effect speeds gastric emptying), acne (long-term low-dose), and chlamydia in pregnancy where azithromycin isn’t available. Four-times-daily dosing is the major drawback.
Side effects: significant GI upset (the prokinetic effect is a feature for gastroparesis, a bug for everyone else), QT prolongation, drug interactions via CYP3A4 inhibition, hepatotoxicity.
Pick for: pertussis, gastroparesis, acne, chlamydia in pregnancy, when azithromycin is unavailable.
7. Doxycycline Capsules (100 mg)
Class: Tetracycline · Manufacturer: WHO-GMP certified · View product
Doxycycline is the second-most-versatile broad-spectrum antibiotic in primary care after amoxicillin/clavulanate. Spectrum: atypical respiratory pathogens, Lyme disease (preferred), rickettsial infections, malaria prophylaxis, acne (long-term low-dose), MRSA skin infections, chlamydia, traveller’s diarrhoea, bacterial vaginosis combinations. Once or twice-daily dosing makes adherence easy. Now also used as on-demand STI post-exposure prophylaxis (200 mg within 72 h after sex — DoxyPEP, IDSA-supported in select populations).
Side effects: photosensitivity (sunburn risk — wear SPF), oesophageal irritation (take with full glass of water, sit upright for 30 min), avoid in pregnancy and children <8 (tooth staining), GI upset.
Pick for: Lyme disease, atypical pneumonia, malaria prophylaxis, acne, MRSA skin infection, chlamydia, DoxyPEP STI prevention.
8. Levomac 750 (Levofloxacin 750 mg)
Class: Fluoroquinolone · Manufacturer: Macleods · View product
Levofloxacin is a respiratory fluoroquinolone with strong coverage of S. pneumoniae (including penicillin-resistant strains), atypicals, and gram-negatives. The 750 mg short-course (5 days) regimen is non-inferior to 7–14-day courses for community-acquired pneumonia. Excellent oral bioavailability — IV-to-oral switch usually possible. Fluoroquinolones are reserved second-line because of FDA black-box warnings.
Side effects: tendon rupture (especially in over-60s, on corticosteroids, or with prior tendon problems — Achilles is most affected); peripheral neuropathy; CNS effects (insomnia, anxiety, rare seizures); aortic dissection signal in older patients; QT prolongation; C. difficile risk; reactive arthritis. Use only when narrower options are inappropriate.
Pick for: resistant or severe pneumonia, complicated UTI/pyelonephritis, prostatitis, when penicillin/macrolide pathways are blocked.
9. Cifran OZ (Ciprofloxacin 500 mg + Ornidazole 500 mg)
Class: Fluoroquinolone + nitroimidazole combination · Manufacturer: Cipla · View product
Cifran OZ pairs ciprofloxacin (gram-negative + atypical coverage) with ornidazole (anaerobic + protozoal coverage). The combination addresses mixed gut infections — bacterial dysentery with Entamoeba or Giardia overlay, post-surgical intra-abdominal infections, and pelvic inflammatory disease combinations. All fluoroquinolone black-box warnings apply.
Pick for: mixed bacterial-protozoal gastrointestinal infection, intra-abdominal sepsis with mixed flora, traveller’s diarrhoea with parasitic overlay.
10. Flagyl (Metronidazole 200/400 mg)
Class: Nitroimidazole · Manufacturer: Sanofi · View product
Metronidazole is the reference nitroimidazole — exclusively active against anaerobic bacteria and certain protozoa (Trichomonas, Giardia, Entamoeba histolytica). Mechanism: anaerobic activation generates reactive nitrogen species that damage microbial DNA. Indispensable for anaerobic gum infections, bacterial vaginosis, intra-abdominal infections (combined with aerobic-active drug), C. difficile colitis (now second-line behind fidaxomicin/vancomycin), and most parasitic infections caused by Giardia or Trichomonas.
Side effects: metallic taste, GI upset, peripheral neuropathy on long courses, disulfiram-like reaction with alcohol (avoid alcohol during course and 48 h after), darkened urine, rare CNS effects (cerebellar dysfunction, encephalopathy).
Pick for: bacterial vaginosis, trichomoniasis, giardiasis, amoebiasis, anaerobic dental infections, C. difficile (mild cases), intra-abdominal anaerobic combinations.
Comparison table: 10 antibiotics at a glance
| Treatment | Class | Spectrum | Best for | Key concern |
|---|---|---|---|---|
| Mox | Aminopenicillin | Streptococci, some gram-neg | Strep throat, otitis, dental | Penicillin allergy |
| Augmentin | Amox + clavulanate | + β-lactamase producers | Bites, severe sinusitis | Diarrhoea, hepatitis |
| Cephadex | 1st-gen cephalosporin | Gram-positive cocci | Cellulitis, mastitis | Penicillin cross-react low |
| Cefix | 3rd-gen cephalosporin | Broader gram-negative | Typhoid, complicated UTI | Resistance trends |
| Asitomycin 500 | Macrolide | Atypicals + respiratory | Atypical pneumonia, chlamydia | QT prolongation |
| Erythromycin | Macrolide | Atypicals + respiratory | Pertussis, gastroparesis | GI side effects, QID dosing |
| Doxycycline | Tetracycline | Atypicals, rickettsia, MRSA | Lyme, malaria prophy, acne | Photosensitivity, pregnancy |
| Levomac 750 | Fluoroquinolone | Broad respiratory + UTI | Resistant pneumonia, prostatitis | Tendon, neuro warnings |
| Cifran OZ | FQ + nitroimidazole | Mixed bacterial+protozoal | Mixed gut infections | FQ class warnings |
| Flagyl | Nitroimidazole | Anaerobes + protozoa | BV, giardiasis, anaerobes | Disulfiram reaction |
Decision shortcut
- Strep throat / otitis / dental abscess: Mox (amoxicillin) first-line.
- Penicillin-allergic with respiratory infection: Asitomycin 500 (azithromycin) or Doxycycline.
- Cellulitis or skin abscess: Cephadex (cephalexin); add Doxycycline if MRSA suspected.
- Animal or human bite: Augmentin (amox/clav) — covers oral flora and skin contamination.
- Atypical pneumonia (Mycoplasma/Chlamydia/Legionella): Asitomycin 500 or Doxycycline.
- Lyme disease (early): Doxycycline 100 mg twice daily for 10–14 days.
- Bacterial vaginosis or trichomoniasis: Flagyl (metronidazole).
- Resistant or severe UTI: Cefix or Levomac 750. For uncomplicated UTI, narrower options (nitrofurantoin, fosfomycin) are preferred where stocked.
- Traveller’s diarrhoea with mixed flora: Cifran OZ (cipro + ornidazole).
- Acne (inflammatory): Doxycycline low-dose long-term.
Frequently asked questions
What is the best antibiotic for common infections?
There’s no single “best” — the right antibiotic depends on the infection, suspected pathogen, allergy history, and local resistance patterns. Amoxicillin (Mox) covers most common community-acquired upper respiratory and dental infections. Augmentin extends coverage when amoxicillin alone is inadequate. Doxycycline and azithromycin cover atypicals and beta-lactam-allergic patients. Pick by indication, not by “strongest.”
Are antibiotics safe?
Generally yes when matched correctly to the infection. Significant adverse effects exist for specific classes — fluoroquinolones carry FDA black-box warnings for tendon, CNS, peripheral nerve, and aortic effects; tetracyclines cause photosensitivity and shouldn’t be used in pregnancy or children <8; macrolides prolong QT interval. Allergic reactions to beta-lactams are uncommon but real. The biggest risks are misuse — taking antibiotics for viral infections (no benefit, all the harm) or stopping early enough to select for resistant strains.
Can I take antibiotics for a cold or flu?
No — colds and flu are viral. Antibiotics don’t shorten viral illness, don’t reduce complications, and expose you to side effects and resistance pressure for nothing. Most sore throats and bronchitis are also viral. Antibiotics are warranted when there’s a clear bacterial focus (strep throat with positive test, sinusitis lasting >10 days with worsening symptoms, pneumonia with focal findings).
Should I always finish the course?
The traditional advice is being reassessed. For many infections, modern evidence supports shorter courses — 3–5 days for uncomplicated UTI, 5–7 days for community-acquired pneumonia, 5 days for cellulitis. The “always finish” principle was overgeneralised; for some infections, the shortest effective course actually limits resistance pressure. Follow the specific course your clinician prescribed, but don’t extend voluntarily.
What’s the difference between azithromycin and amoxicillin?
Different mechanisms (azithromycin blocks protein synthesis; amoxicillin blocks cell-wall synthesis), different spectrum (azithromycin covers atypicals; amoxicillin covers narrower bacterial range), different course lengths (azithromycin 3–5 days; amoxicillin 7–10 days). Azithromycin is preferred for atypical respiratory pathogens or beta-lactam-allergic patients; amoxicillin for typical bacterial pneumonia, strep throat, and dental infections.
Can I drink alcohol on antibiotics?
Drug-specific. Metronidazole (Flagyl) and tinidazole produce a clear disulfiram-like reaction with alcohol — avoid alcohol during course and 48 hours after. Linezolid and erythromycin have weaker interactions. Most other antibiotics (amoxicillin, doxycycline, cephalosporins) don’t produce a clinically important alcohol interaction, though heavy drinking can compound nausea or impair recovery.
Why are fluoroquinolones reserved second-line?
FDA black-box warnings — tendon rupture (especially Achilles, especially over-60s and patients on corticosteroids), peripheral neuropathy that can become permanent, CNS effects (insomnia, anxiety, rare seizures), aortic dissection signal, prolonged QT, and increased C. difficile risk. The 2016 FDA safety communication recommended fluoroquinolones for uncomplicated infections only when no alternative exists. They remain essential for severe pneumonia, prostatitis, and complicated UTIs.
What is DoxyPEP?
Doxycycline post-exposure prophylaxis — 200 mg single dose taken within 72 hours after sex, shown in trials to reduce subsequent diagnoses of chlamydia, syphilis, and gonorrhoea by 60–80% in MSM and trans women on PrEP. CDC and IDSA support it for selected populations. Effectiveness in cisgender women has been less consistent in trials.
Bottom line
Match the antibiotic to the infection, not the other way around. Amoxicillin and Augmentin cover most community bacterial infections. Doxycycline and azithromycin cover atypicals and penicillin-allergic patients. Cephalosporins cover skin and complicated UTI. Fluoroquinolones are powerful but reserved due to black-box warnings. Metronidazole covers anaerobes and protozoa. When in doubt about whether you need an antibiotic at all, see a clinician — most respiratory and gut illness is viral and antibiotics won’t help.
Related guides: Best antiparasitic medications 2026 · All antibiotics products · Doxycycline vs azithromycin compared
For a broader overview of bacterial infections, diagnosis, and antibiotic selection by infection type, see our complete bacterial infection guide.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.